Millennium Initiates Two Phase Il Trials of Aurora A Kinase Inhibitor
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Millennium Pharmaceuticals, Inc., announced that Millennium has initiated two Phase II clinical trials of MLN8237.
The first trial will examine the molecule in adult patients with aggressive non-Hodgkin’s lymphoma (NHL), while the second trial will evaluate the drug in patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). MLN8237 is an oral, selective Aurora A kinase inhibitor discovered and developed by Millennium scientists.
“We are very excited to begin these studies examining MLN8237 in several hematologic malignancies,” said Nancy Simonian, M.D., Chief Medical Officer, Millennium. “This novel target is the latest drug candidate in our expanded oncology pipeline to enter Phase II clinical trials and helps move Millennium and Takeda toward the goal of becoming a global oncology leader.”
Both trials will be open-label, multi-center trials for patients with relapsed or refractory aggressive NHL, AML and MDS. Endpoints to be examined include response rates, time to progression and safety and tolerability. These trials are the first of a broader Phase II program examining the use of MLN8237 in both solid tumors and hematologic malignancies. An additional study is ongoing with the Children’s Oncology Group examining MLN8237 in pediatric neuroblastoma.
The first trial will examine the molecule in adult patients with aggressive non-Hodgkin’s lymphoma (NHL), while the second trial will evaluate the drug in patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). MLN8237 is an oral, selective Aurora A kinase inhibitor discovered and developed by Millennium scientists.
“We are very excited to begin these studies examining MLN8237 in several hematologic malignancies,” said Nancy Simonian, M.D., Chief Medical Officer, Millennium. “This novel target is the latest drug candidate in our expanded oncology pipeline to enter Phase II clinical trials and helps move Millennium and Takeda toward the goal of becoming a global oncology leader.”
Both trials will be open-label, multi-center trials for patients with relapsed or refractory aggressive NHL, AML and MDS. Endpoints to be examined include response rates, time to progression and safety and tolerability. These trials are the first of a broader Phase II program examining the use of MLN8237 in both solid tumors and hematologic malignancies. An additional study is ongoing with the Children’s Oncology Group examining MLN8237 in pediatric neuroblastoma.
